Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J. Sweeney, Sonia Yip, Alison Y. Zhang et al.|The Lancet Oncology|2023Cited by 195
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastomaLucy Gately, Carmen Balañá, Carlos Mesía et al.|Journal of Neuro-Oncology|2023Cited by 5
Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastomaLucy Gately, Carmen Balañá, Carlos Mesía et al.|Journal of Neuro-Oncology|2024Cited by 3
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)Lucy Gately, Carmen Balañá, Carlos Mesía et al.|Journal of Neuro-Oncology|2024Cited by 2
CTNI-54. A COMBINED ANALYSIS OF TWO RANDOMISED STUDIES EXPLORING THE IMPACT OF EXTENDED POST-RADIATION TEMOZOLOMIDE ON SURVIVAL OUTCOMES IN NEWLY DIAGNOSED GLIOBLASTOMALucy Gately, Carmen Balañá, Carlos Mesía et al.|Neuro-Oncology|2023Cited by 0